Nasal NK/ @entity784 is an @entity9653 -related, highly aggressive but localized disease in Orientals. The median survival is <1 year. Here, we update our experience on 18 @entity1 treated with autologous stem cell transplantation (ASCT). Two @entity1 died of @entity33 and @entity295 during ASCT. Relapse occurred in nine cases, including six local relapses. Compared with @entity1 treated in remission, all @entity1 treated in active or disseminated disease died of early relapse. Within this cohort, there was no significant survival difference between @entity1 treated in first ( @entity3432 , n = 7) or second ( @entity10911 , n = 5) complete remissions. However, among consecutive cases analyzed, the @entity1 receiving ASCT at @entity3432 showed a trend towards better overall survival compared with historical matched controls (P = 0.064). Disease relapse beyond 6 months was not seen after ASCT. Our retrospective data suggest that ASCT in @entity3432 is a viable consolidation therapy for local-stage NK/ @entity784 , but a randomized trial is needed to prove any definite survival benefit. For @entity1 with relapsed, refractory or extranasal disease, early consideration for allogeneic transplantation and alternative therapy may be warranted.

Autologous stem cell transplantation for nasal NK/ XXXX : a progress report on its value.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3432 :: ('1378', 'Gene') :: ['CR1'] @entity10911 :: ('1380', 'Gene') :: ['CR2'] @entity295 :: ('MESH:D018805', 'Disease') :: ['septicemia'] @entity784 :: ('MESH:D016399', 'Disease') :: ['T lymphoma', 'T-cell lymphoma'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity9653 :: ('10376', 'Species') :: ['Epstein-Barr virus']
@entity784 :: (MESH:D016399,Disease) :: ['T-cell lymphoma']
